03rd week of 2020 patent applcation highlights part 8 |
Patent application number | Title | Published |
20200016102 | Methods for the treatment of chronic hypoxemia and inhibiting lung fibrosis in patients with pulmonary fibrosis with and without COPD | 2020-01-16 |
20200016103 | COMPOSITIONS AND METHODS TO MODULATE CHLORIDE ION CHANNEL ACTIVITY | 2020-01-16 |
20200016104 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF FAT INFILTRATION IN MUSCLE | 2020-01-16 |
20200016105 | COMPOSITIONS AND USES THEREOF FOR THE TREATMENT OF CHRONIC FELINE RESPIRATORY DISORDERS | 2020-01-16 |
20200016106 | COMPOSITION FOR INHIBITING GROWTH OF BACTERIUM HAVING MENAQUINONE SYNTHESIS PATHWAY THROUGH FUTALOSINE OR FUTALOSINE DERIVATIVE | 2020-01-16 |
20200016107 | COMPOSITION AND METHOD FOR THE TOPICAL TREATMENT OF SEVERE ACNE | 2020-01-16 |
20200016108 | OPHTHALMIC COMPOSITIONS CONTAINING A NITRIC OXIDE RELEASING PROSTAMIDE | 2020-01-16 |
20200016109 | COMPOUNDS CONTAINING S-N-VALERYL-N-{[2'-(1H-TETRAZOLE-5-YL)-BIPHENYL-4-YL]-METHYL}-VALINE AND (2R,4S)-5-BIPHENYL-4-YL-4-(3-CARBOXY-PROPIONYLAMINO)-2-METHYL-PENTANOIC ACID ETHYL ESTER MOIETIES AND CATIONS | 2020-01-16 |
20200016110 | COMPOUNDS CONTAINING S-N-VALERYL-N-{[2'-(1H-TETRAZOLE-5-YL)-BIPHENYL-4-YL]-METHYL}-VALINE AND (2R,4S)-5-BIPHENYL-4-YL-4-(3-CARBOXY-PROPIONYLAMINO)-2-METHYL-PENTANOIC ACID ETHYL ESTER MOIETIES AND CATIONS | 2020-01-16 |
20200016111 | Prodrugs of Fumarates and Their Use in Treating Various Diseases | 2020-01-16 |
20200016112 | POLYUNSATURATED FATTY ACID MONOGLYCERIDES, COMPOSITIONS, METHODS AND USES THEREOF | 2020-01-16 |
20200016113 | PROCESS FOR PREPARING SUPRAMOLECULAR PLATINUM-BASED COMPOUNDS | 2020-01-16 |
20200016114 | FAP-ACTIVATED THERAPEUTIC AGENTS, AND USES RELATED THERETO | 2020-01-16 |
20200016115 | TOPICAL MASSAGE OIL AND CREAM CONTAINING CBD, CBN, CURCUMIN AND BOSWELLIA RESIN | 2020-01-16 |
20200016117 | COMPOSITIONS AND METHODS FOR PREVENTING AND RECOVERY FROM DETRIMENTAL EFFECTS OF ALCOHOL CONSUMPTION | 2020-01-16 |
20200016118 | HDAC INHIBITOR IN COMBINATION WITH VEGF/VEGFR INTERACTION FOR CANCER THERAPY BASED ON PLATELET COUNT | 2020-01-16 |
20200016119 | PHARMACEUTICAL COMPOSITION | 2020-01-16 |
20200016120 | PHARMACEUTICAL COMPOSITION | 2020-01-16 |
20200016121 | COMPOUNDS AND METHODS FOR TREATMENT OF INFLAMMATORY BOWEL DISEASE WITH EXTRA-INTESTINAL MANIFESTATIONS | 2020-01-16 |
20200016122 | METHOD FOR REDUCING ITCHING IN ATOPIC DERMATITIS | 2020-01-16 |
20200016123 | COMPOSITIONS AND METHODS FOR INHIBITING BRAIN TRAUMA-INDUCED NEURODEGENERATION AND RELATED CONDITIONS | 2020-01-16 |
20200016124 | COMPOSITIONS AND METHODS FOR REDUCING WEIGHT GAIN | 2020-01-16 |
20200016125 | GRANZYME B INHIBITOR COMPOSITIONS AND METHODS FOR THE PREVENTION AND/OR TREATMENT OF SKIN BLISTERING AND/OR PEELING | 2020-01-16 |
20200016126 | NOVEL TEBIPENEM PIVOXIL IMMEDIATE AND MODIFIED RELEASE ORAL DOSAGE FORMS | 2020-01-16 |
20200016127 | COMPOSITIONS AND METHODS FOR TREATING SYNUCLEINOPATHIES | 2020-01-16 |
20200016128 | THERAPEUTIC USE OF LEVOROTATORY B-LACTAMS IN HEMATOPOIESIS, IMMUNO-ONCOLOGY THERAPY, AND REGULATION OF LIPOPROTEIN AND APOLIPOPROTEIN LEVELS | 2020-01-16 |
20200016129 | COMPOUNDS FOR USE IN THE PREVENTION AND/OR TREATMENT OF NON-ALCOHOLIC FAT LIVER DISEASE AND NON-ALCOHOLIC STEATOHEPATITIS | 2020-01-16 |
20200016130 | Methods of Diagnosing and Treating Small Cell Lung Cancer Using Polo-Like Kinase 1 (PLK1) Inhibitors | 2020-01-16 |
20200016131 | Bach1 Inhibitors in Combination with Nrf2 Activators and Pharmaceutical Compositions Thereof | 2020-01-16 |
20200016132 | COMPOSITION FOR INHIBITING SODIUM LEAK CHANNEL (NALCN), COMPRISING N-BENZHYDRYL QUINUCLIDINE DERIVATIVES | 2020-01-16 |
20200016133 | PREVENTION AND TREATMENT OF THROMBOSIS IN MEDICALLY ILL PATIENTS | 2020-01-16 |
20200016134 | COMPOSITIONS AND METHODS FOR TREATING SUBSTANCE ABUSE DISORDERS | 2020-01-16 |
20200016135 | AMIDE DERIVATIVES AS NAV1.7 AND NAV1.8 BLOCKERS | 2020-01-16 |
20200016136 | PYRIDIN-3-YL ACETIC ACID DERIVATIVES AS INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | 2020-01-16 |
20200016137 | Compositions and Methods for Treatment of Edema | 2020-01-16 |
20200016138 | GEL CONTAINING PIRFENIDONE | 2020-01-16 |
20200016139 | PHARMACEUTICAL COMBINATION COMPRISING A T-TYPE CALCIUM CHANNEL BLOCKER | 2020-01-16 |
20200016140 | AZOLE COMPOUNDS AS UBIQUITIN-SPECIFIC PROTEASE USP7 INHIBITORS | 2020-01-16 |
20200016141 | INDAZOLE INHIBITORS OF FRUCTOKINASE (KHK) AND METHODS OF USE IN TREATING KHK-MEDIATED DISORDERS OR DISEASES | 2020-01-16 |
20200016142 | NIRAPARIB FORMULATIONS | 2020-01-16 |
20200016143 | 3-(5-AMINO-1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND USES THEREOF | 2020-01-16 |
20200016144 | Method for Assessing the Efficacy of IMIDS and Composition or Combination for Use in Treating IMID Sensitive Diseases | 2020-01-16 |
20200016145 | TREATMENT OF CHRONIC TRAUMATIC ENCEPHALOPATHY | 2020-01-16 |
20200016146 | COMPOSITIONS AND METHODS FOR TREATING HELICOBACTER PYLORI INFECTION | 2020-01-16 |
20200016147 | SMALL-MOLECULE UT-A-SELECTIVE UREA TRANSPORT INHIBITORS | 2020-01-16 |
20200016148 | ANALOGS OF DEUTETRABENAZINE, THEIR PREPARATION AND USE | 2020-01-16 |
20200016149 | MULTI-ARM POLYMER PRODRUGS | 2020-01-16 |
20200016150 | TREATMENT OF THE PRURITIC SYMPTOMS OF LIVER DISEASE | 2020-01-16 |
20200016151 | NOVEL NAPHTHYLENYL COMPOUNDS FOR LONG-ACTING INJECTABLE COMPOSITIONS AND RELATED METHODS | 2020-01-16 |
20200016152 | TREATMENT OF DISEASES | 2020-01-16 |
20200016153 | METHOD AND THERAPEUTIC/COSMETIC TOPICAL COMPOSITIONS FOR THE TREATMENT OF ROSACEA AND SKIN ERYTHEMA USING A1-ADRENOCEPTOR AGONISTS | 2020-01-16 |
20200016154 | COMBINATION THERAPY | 2020-01-16 |
20200016155 | COMPOSITIONS AND TREATMENT OF HEART DEFICIENCY IN NON-HUMAN ANIMALS | 2020-01-16 |
20200016156 | Compositions and Methods For Targeting Cancers | 2020-01-16 |
20200016157 | Inhibitors of Multidrug Resistance Transporter P-Glycoprotein | 2020-01-16 |
20200016158 | SALT OF A PYRIMIDO[6,1-A]ISOQUINOLIN-4-ONE COMPOUND | 2020-01-16 |
20200016159 | N3-CYCLICALLY SUBSTITUTED THIENOURACILS AND USE THEREOF | 2020-01-16 |
20200016160 | Treatment Agents for Inhibiting HIV and Cancer in HIV Infected Patients | 2020-01-16 |
20200016161 | METHODS FOR TREATING VIRAL DISORDERS | 2020-01-16 |
20200016162 | INHIBITORS OF HUMAN EZH2, AND METHODS OF USE THEREOF | 2020-01-16 |
20200016163 | TREATMENT OF DEMENTIA WITH CANNABINOID AGONISTS | 2020-01-16 |
20200016164 | METHODS OF TREATING PRADER WILLI SYNDROME AND CONDITIONS ASSOCIATED WITH LOW BASAL METABOLIC RATE OR HYPERPHAGIA USING A KATP CHANNEL OPENER | 2020-01-16 |
20200016165 | ADMINISTRATION AND DOSAGE OF DIAMINOPHENOTHIAZINES | 2020-01-16 |
20200016166 | DRUG-INDUCED EPIGENETIC REMODELING TO PREVENT FIBROSIS | 2020-01-16 |
20200016167 | Methods for Treating Hyperbilirubinemia with Stannsoporfin | 2020-01-16 |
20200016168 | COMPOSITIONS AND METHODS FOR REACTIVATING LATENT HIV-1 INFECTIONS | 2020-01-16 |
20200016169 | OPHTHALMIC SOLUTION OF BIMATOPROST | 2020-01-16 |
20200016170 | Oil-in-Oil emulsified polymeric implants containing a hypotensive lipid and related methods | 2020-01-16 |
20200016171 | CORTICOSTEROID CONTAINING ORALLY DISINTEGRATING TABLET COMPOSITIONS FOR EOSINOPHILIC ESOPHAGITIS | 2020-01-16 |
20200016172 | ORAL PHARMACEUTICAL PRODUCTS AND METHODS OF USE COMBINING TESTOSTERONE ESTERS WITH HYPOLIPIDEMIC AGENTS | 2020-01-16 |
20200016173 | Use of Exemestane for the Treatment of Gastric Cancer | 2020-01-16 |
20200016174 | PHARMACEUTICAL COMPOSITION | 2020-01-16 |
20200016175 | PHARMACEUTICAL COMPOSITION | 2020-01-16 |
20200016176 | COMPOSITIONS FOR THE TREATMENT OF CATARACTS | 2020-01-16 |
20200016177 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR REPROGRAMING IMMUNE ENVIRONMENT IN A SUBJECT IN NEED THEREOF | 2020-01-16 |
20200016178 | 19-NOR C3, 3-DISUBSTITUTED C21-C-BOUND HETEROARYL STEROIDS AND METHODS OF USE THEREOF | 2020-01-16 |
20200016179 | Prodrugs of 2,4-Pyrimidinediamine Compounds and Their Uses | 2020-01-16 |
20200016180 | NOVEL PRODRUGS OF NUCLEOSIDE PHOSPHONATES | 2020-01-16 |
20200016181 | METHOD FOR TREATING CANCER USING A COMBINATION OF DNA-DAMAGING AGENTS AND DNA-PK INHIBITORS | 2020-01-16 |
20200016182 | STAT5a AND ITS FUNCTIONAL TUMOR SUPPRESSOR ANALOGS FOR TREATMENT OF MALIGNANCIES EXPRESSING NPM/ALK AND OTHER ONCOGENIC KINASES | 2020-01-16 |
20200016183 | SKIN PIGMENTATION INHIBITOR | 2020-01-16 |
20200016184 | Compositions Containing Enriched Natural Crocin and/or Crocetin, and Their Therapeutic or Nutraceutical Uses | 2020-01-16 |
20200016185 | SENOLYTIC COMPOSITIONS AND USES THEREOF | 2020-01-16 |
20200016186 | PHARMACEUTICAL COMPOSITION FOR PREVENTING AND TREATING GLAUCOMA, CONTAINING ADENOSINE DERIVATIVE | 2020-01-16 |
20200016187 | MODIFICATION OF THE PH AND OTHER PHYSICAL PROPERTIES OF NICOTINAMIDE ADENINE DINUCLEOTIDE (OXIDIZED FORM) TO ALLOW FOR ENHANCED STABILITY AND MULTIPLE DELIVERY SYSTEMS | 2020-01-16 |
20200016188 | MODIFICATION OF THE PH AND OTHER PHYSICAL PROPERTIES OF NICOTINAMIDE ADENINE DINUCLEOTIDE (OXIDIZED FORM) TO ALLOW FOR ENHANCED STABILITY AND MULTIPLE DELIVERY SYSTEMS | 2020-01-16 |
20200016189 | METHOD FOR TREATING SCHIZOPHRENIA | 2020-01-16 |
20200016190 | SUBLINGUAL ADMINISTRATION OF VITAMIN B12 DISPERSED IN A HYDROPHOBIC CONTINUOUS PHASE | 2020-01-16 |
20200016191 | COMPOSITION FOR SKIN INJECTION | 2020-01-16 |
20200016192 | PREVENTATIVE MANNOSE THERAPY AND TREATMENT OF VIRAL INFECTIONS USING MANNOSE-CONTAINING COMPOSITIONS | 2020-01-16 |
20200016193 | SODIUM NITRITE-CONTAINING PHARMACEUTICAL COMPOSITIONS | 2020-01-16 |
20200016194 | HALOGEN TREATMENT OF HEART ATTACK AND ISCHEMIC INJURY | 2020-01-16 |
20200016195 | WATER-SOLUBLE NANOCERIA AND METHODS OF MAKING AND USING THE SAME | 2020-01-16 |
20200016196 | ARSENIC COMPOSITIONS | 2020-01-16 |
20200016197 | METHODS AND COMPOSITIONS FOR USE IN THE PREVENTION, TREATMENT AND/OR ALLEVIATION OF CANCER | 2020-01-16 |
20200016198 | COMPOSITION FOR USE IN IMMUNOTHERAPY | 2020-01-16 |
20200016199 | METHODS FOR THE TREATMENT OF B CELL MALIGNANCIES USING ADOPTIVE CELL THERAPY | 2020-01-16 |
20200016200 | MODULATING CYTOTOXIC CELL LYTIC GRANULE POSITIONING TO PROMOTE DIFFUSE KILLING IN CELLULAR THERAPIES | 2020-01-16 |
20200016201 | CHIMERIC ANTIGEN RECEPTORS AND COMPOSITIONS AND METHODS OF USE THEREOF | 2020-01-16 |
20200016202 | MODULATION OF NOVEL IMMUNE CHECKPOINT TARGETS | 2020-01-16 |